Press release
ProBioGen Is Granted Divisional Patent on Its Proprietary AGE1 Cell Line
ProBioGen AG, a leading biotechnology company in cell engineering and production of biopharmaceuticals, today announced that it has been granted a divisional patent on its AGE1 cell line.The patent covers the production of Modified Vaccinia Ankara (MVA) in duck cell lines. As these cells are free from endogenous particle-associated retrovirus activity, they are superior to current production substrates derived from chicken. The discovery has wide implications for the industrial production of one of the most promising recombinant vaccine vectors against infectious disease challenges such as HIV and malaria.
“The granted divisional patent further strengthens ProBioGen's proprietary platform that extends from innovative host cell lines to chemically defined production processes for highly attenuated viruses,” said Dr. Volker Sandig, Chief Scientific Officer of ProBioGen. An additional application on AGE1 with yet broader implications has been filed.
About ProBioGen AG
ProBioGen is a leading cell specialist. By combining deep molecular understanding of cells with state-of-the-art industry process engineering and production know-how, ProBioGen’s technologies enable biopharmaceutical companies to develop products with superior efficiency, safety and a more favourable cost profile. Since its inception in 1994, the company has processed more than 300 cell lines and established a GMP unit based on disposable reactor technology, which supports all currently available manufacturing processes. The company is headquartered in Berlin.
Contact for ProBioGen:
Dr Gertraud Unterrainer, CFO
Goethestrasse 54
13086 Berlin
Tel.: +49 (0)30 924 006-0
Fax: +49 (0)30 924 006-19
email: info@probiogen.de
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ProBioGen Is Granted Divisional Patent on Its Proprietary AGE1 Cell Line here
News-ID: 125768 • Views: …
More Releases for AGE1
Cytomegalovirus (CMV) Treatment market Research Report on Growth, Share, Value, …
Global Cytomegalovirus (CMV) Treatment market Size, Status, and forecast for the 2025-2032. The research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Cytomegalovirus (CMV) Treatment market industry, as well as predicted future…
Veterinary Drug Market Will Generate Record Revenue by 2029
Veterinary drug market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to accelerate the growth of the market during the forecast period include the increasing burden of chronic diseases among animals, the growing adoption of pets, and the increase in drug preferences by pet and poultry farm owners, coupled with increased demand for meat and animal-based products. As per the…
Autogenous Vaccines Market Business overview, Upcoming Trends, Growth, Analysis …
The global autogenous vaccines market is anticipated to grow at a significant CAGR during the forecast period (2022-2028).
Autogenous vaccines for veterinary can be defined as any immunological veterinary medicinal products which are manufactured for the purpose of producing active immunity from pathogenic organisms obtained from an animal which have the same herd that has been inactivated and used for the treatment of this animal. Autogenous vaccines are derived from…
Autogenous Vaccines Market Analysis By Industry Size, Share, Revenue Growth Dema …
The global autogenous vaccines market is anticipated to grow at a significant CAGR during the forecast period (2022-2028).
Autogenous vaccines for veterinary can be defined as any immunological veterinary medicinal products which are manufactured for the purpose of producing active immunity from pathogenic organisms obtained from an animal which have the same herd that has been inactivated and used for the treatment of this animal. Autogenous vaccines are derived from pathogens.…
ProBioGen Announces the Appointment of Dr. Volker Sandig to Chief Scientific Off …
Former CSO Dr. Uwe Marx leaves for academia -
Berlin, March 31, 2010 - ProBioGen AG, a leading biotechnology company in cell engineering and production of biopharmaceuticals, today announced that Dr. Volker Sandig has been appointed to Chief Scientific Officer (CSO) of the company. He will take over the duties of Dr. Uwe Marx, who will take an opportunity to lead an entrepreneurial innovation team at the Technical University Berlin.…
